Pharmacokinetics of oral and intravenous cannabidiol and its antidepressant-like effects in chronic mild stress mouse model

Xu, Chen; Chang, Tanran; Du, Yaqi; Yu, Chaohui; Tan, Xin; Li, Xiangdong

doi:10.1016/j.etap.2019.103202

Cited by 80 publications

(71 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent studies have shown that the antidepressant effect promoted by the systemic administration of CBD in mice submitted to the forced swimming test is associated with increased expression of synaptophysin, PSD95 (synaptic plasticity marker) and BDNF levels in medial prefrontal cortex (PFC) ( Sales et al, 2019 ). The similar effects were described in mice submitted previously to chronic mild stress mouse model ( Xu et al, 2019 ). Indeed, preceding research shows that CBD injection into the ventral medial PFC also induces antidepressant like behavior ( Sartim et al, 2016 ).…”

Section: The Great Potential Of Cbd As An Alternative To Treat Neuropsupporting

confidence: 79%

Glial Cells and Their Contribution to the Mechanisms of Action of Cannabidiol in Neuropsychiatric Disorders

et al. 2021

View full text Add to dashboard Cite

Cannabidiol (CBD) is a phytocannabinoid with a broad-range of therapeutic potential in several conditions, including neurological (epilepsy, neurodegenerative diseases, traumatic and ischemic brain injuries) and psychiatric disorders (schizophrenia, addiction, major depressive disorder, and anxiety). The pharmacological mechanisms responsible for these effects are still unclear, and more than 60 potential molecular targets have been described. Regarding neuropsychiatric disorders, most studies investigating these mechanisms have focused on neuronal cells. However, glial cells (astrocytes, oligodendrocytes, microglia) also play a crucial role in keeping the homeostasis of the central nervous system. Changes in glial functions have been associated with neuropathological conditions, including those for which CBD is proposed to be useful. Mostly in vitro studies have indicated that CBD modulate the activation of proinflammatory pathways, energy metabolism, calcium homeostasis, and the proliferative rate of glial cells. Likewise, some of the molecular targets proposed for CBD actions are f expressed in glial cells, including pharmacological receptors such as CB1, CB2, PPAR-γ, and 5-HT1A. In the present review, we discuss the currently available evidence suggesting that part of the CBD effects are mediated by interference with glial cell function. We also propose additional studies that need to be performed to unveil the contribution of glial cells to CBD effects in neuropsychiatric disorders.

show abstract

Section: The Great Potential Of Cbd As An Alternative To Treat Neuropsupporting

confidence: 79%

Glial Cells and Their Contribution to the Mechanisms of Action of Cannabidiol in Neuropsychiatric Disorders

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Following this exposure, rodents exhibited depressive-like behavioral alterations, mainly a persistent reduction of their responsiveness to pleasurable stimuli, such as a palatable sucrose solution [147,148]. In this model, different doses and routes of CBD administration prevented anxiogenic and depressogenic-like behaviors and displayed a neuroprotective effect [116,134,149] through CB 1 r and CB 2 r [116,131]. Indeed, culture cell studies showed that CBD induced progenitor proliferation and cell cycle progression, depending on CB 1 r and CB 2 r activation and anandamide increase [149].…”

Section: Results From Animal Studiesmentioning

confidence: 99%

Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders

et al. 2020

View full text Add to dashboard Cite

The potential therapeutic use of some Cannabis sativa plant compounds has been attracting great interest, especially for managing neuropsychiatric disorders due to the relative lack of efficacy of the current treatments. Numerous studies have been carried out using the main phytocannabinoids, tetrahydrocannabinol (THC) and cannabidiol (CBD). CBD displays an interesting pharmacological profile without the potential for becoming a drug of abuse, unlike THC. In this review, we focused on the anxiolytic, antidepressant, and antipsychotic effects of CBD found in animal and human studies. In rodents, results suggest that the effects of CBD depend on the dose, the strain, the administration time course (acute vs. chronic), and the route of administration. In addition, certain key targets have been related with these CBD pharmacological actions, including cannabinoid receptors (CB1r and CB2r), 5-HT1A receptor and neurogenesis factors. Preliminary clinical trials also support the efficacy of CBD as an anxiolytic, antipsychotic, and antidepressant, and more importantly, a positive risk-benefit profile. These promising results support the development of large-scale studies to further evaluate CBD as a potential new drug for the treatment of these psychiatric disorders.

show abstract

“…A mouse depression model showed significant antidepressantlike effect after administration of CBD. The animals showed increased engagement on pleasurable activities [53].…”

Section: Depressionmentioning

confidence: 97%

The Impact of Cannabidiol on Psychiatric and Medical Conditions

Oberbarnscheidt

Miller

2020

J Clin Med Res

View full text Add to dashboard Cite

Cannabidiol (CBD) is a substance chemically derived from Cannabis sativa and discussed to be non-psychoactive. According to the FDA, marijuana is classified as a schedule I substance; however, hemp which is defined as extracts from marijuana including cannabinoids containing less than 0.3% tetrahydrocannabinol (THC), is excluded from that controlled substance act and available at local convenience stores in the US as it is seen as an herbal supplement. CBD is purported to be used for various medical and psychiatric conditions: depression, anxiety, post-traumatic stress disorder, Alzheimer's or other cognitive illnesses as well as pain. There is also a new trend to use CBD for the treatment of opioid use disorder. The one CBD product on the market that is FDA approved for the treatment of childhood epilepsy forms Dravet and Lennox-Gastaut syndromes is available under the name Epidiolex. There is a significant difference between this medication and the over-the-counter CBD products that contain very inconsistent strengths of CBD, if they contain it at all, and vary in percentage even from sample to sample. Frequently the so-called CBD products are not containing any CBD at all, but mostly containing THC. This article is a systematic review of literature reviewing the available clinical data on CBD, for use in various medical and psychiatric conditions with focus on a review of the pharmacology and toxicity. Resources used were ORVID, PubMed, MEDLINE, PsychINFO, EMBASE with keywords CBD, cannabidiol, hemp and cannabinoids.

show abstract

Pharmacokinetics of oral and intravenous cannabidiol and its antidepressant-like effects in chronic mild stress mouse model

Cited by 80 publications

References 54 publications

Glial Cells and Their Contribution to the Mechanisms of Action of Cannabidiol in Neuropsychiatric Disorders

Glial Cells and Their Contribution to the Mechanisms of Action of Cannabidiol in Neuropsychiatric Disorders

Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders

The Impact of Cannabidiol on Psychiatric and Medical Conditions

Contact Info

Product

Resources

About